BioInvent International AB

BioInvent International AB is a biotechnology-focused company operating in the healthcare sector. It primarily engages in the discovery and development of novel immuno-oncology antibodies. These antibodies are designed to target the immune system for the treatment of various types of cancer, aiming to improve efficacy and patient outcomes in oncological therapies. BioInvent’s innovative approach is centered around its patented F.I.R.S.T.™ technology, which stands for functional and relevant in vivo screening for identifying and functionally characterizing antibodies. This platform allows the company to identify new therapeutic targets and select antibodies that modulate the immune response against tumors. The company collaborates with international partners in both academia and the pharmaceutical industry to enhance its development pipeline and bring potential therapies to market. BioInvent International AB plays a significant role in the advancement of cancer immunotherapy, a rapidly evolving and crucial area within the global healthcare landscape. Headquartered in Sweden, BioInvent contributes to the scientific community with its commitment to research and development in cancer treatment.